A Phase 1b, Open-Label Study of Eftozanermin Alfa in Combination with Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Richardson, Paul G.
Polepally, Akshanth R.
Motwani, Monica
Mu, Yunming
Salman, Zeena
Penugonda, Sudhir
Moreau, Philippe
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-137037
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
    Mellqvist, U. H.
    Paba-Prada, C.
    Palumbo, A.
    Plesner, T.
    Sonneveld, P.
    Voorhees, P.
    Byrne, C.
    Harmenberg, J.
    Nordstrom, E.
    Richardson, P. G.
    HAEMATOLOGICA, 2014, 99 : 375 - 376
  • [32] A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    De La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina J.
    Hungria, Vania
    Salwender, Hans J.
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Freise, Kevin J.
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy
    Ward, James E.
    Maciag, Paulo
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E31 - E31
  • [33] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma
    Moreau, Philippe
    Mateos, Maria-Victoria
    Blade, Joan
    Benboubker, Lotfi
    de la Rubia, Javier
    Facon, Thierry
    Comenzo, Raymond L.
    Fay, Joseph W.
    Qin, Xiang
    Masterson, Tara
    Schecter, Jordan
    Ahmadi, Tahamtan
    San Miguel, Jesus
    BLOOD, 2014, 124 (21)
  • [35] Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study
    Grammatico, Sara
    Bringhen, Sara
    Vozella, Federico
    Siniscalchi, Agostina
    Boccadoro, Mario
    Petrucci, Maria Teresa
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2738 - 2740
  • [36] Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma
    Suzuki, Kenshi
    Sunami, Kazutaka
    Matsumoto, Morio
    Maki, Akio
    Shimada, Fumika
    Suzuki, Kazuyuki
    Shimizu, Kazuyuki
    ACTA HAEMATOLOGICA, 2021, 144 (03) : 264 - 274
  • [37] Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM)
    Fu, Chengcheng
    Chen, Zi
    Li, Wensi
    Men, Lichuang
    Wu, Depei
    Yang, Dajun
    Zhai, Yifan
    BLOOD, 2021, 138
  • [38] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
    Richardson, Paul G.
    Oriol, Albert
    Beksac, Meral
    Liberati, Anna Marina
    Galli, Monica
    Schjesvold, Fredrik
    Lindsay, Jindriska
    Weisel, Katja
    White, Darrell
    Facon, Thierry
    Miguel, Jesus Son
    Sunami, Kazutaka
    O'Gorman, Peter
    Sonneveld, Pieter
    Robak, Pawel
    Semochkin, Sergey
    Schey, Steve
    Yu, Xin
    Doerr, Thomas
    Bensmaine, Amine
    Biyukov, Tsvetan
    Peluso, Teresa
    Zaki, Mohamed
    Anderson, Kenneth
    Dimopoulos, Meletios
    LANCET ONCOLOGY, 2019, 20 (06): : 781 - 794
  • [39] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [40] SUBCUTANEOUS DARATUMUMAB IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION PHASE 1B STUDY (PAVO)
    Mateos, M., V
    Chari, A.
    Nah, H.
    Lokhorst, H.
    Kaufman, J. L.
    Moreau, P.
    Oriol, A.
    Plesner, T.
    Benboubker, L.
    Hellemans, P.
    Masterson, T.
    Clemens, P. L.
    Liu, K.
    San-Miguel, J.
    Usmani, S. Z.
    HAEMATOLOGICA, 2018, 103 : 32 - 33
12345